IgA肾病合并Alport综合征的系统综述
该研究回顾性分析本中心儿童IgA肾病合并Alport综合征(IgAN-AS)患者并进行Gd-IgA1免疫染色,同时系统检索多个数据库。共纳入81例来自72个家庭的患者,儿童肾病范围蛋白尿显著多于成人(73.7% vs. 8.8%)。中位随访至16.0岁时40.7%达到肾脏终点,提示该病异质性强且肾脏结局可能不佳。
要点
- 儿童IgAN-AS肾病范围蛋白尿比例显著高于成人(73.7% vs. 8.8%)。
- 基因检测在77例患者中鉴定出66种COL4A3/A4/A5致病性变异。
- 随访患者中40.7%达到肾脏终点,提示预后可能不佳。
核心结论
- IgAN-AS是一种异质性疾病,肾脏结局可能不佳。
- 部分患者同时存在免疫与结构损伤,高敏感度和特异度的IgAN生物标志物可能有助于疾病分层。
研究设计与样本
- 回顾性分析本中心儿童IgAN-AS患者并对肾活检标本行Gd-IgA1免疫染色。
- 系统检索PubMed、Scopus、Web of Science、万方数据和中国知网。
- 共纳入81例来自72个家庭的IgAN-AS患者。
主要发现
- 显微镜下血尿为普遍表现。
- 肾病范围蛋白尿在儿童中显著多于成人(73.7% vs. 8.8%)。
- 病理显示系膜区IgA优势沉积伴肾小球基底膜异常,其中变薄占69.5%(41/59),典型AS相关改变占28.8%(17/59)。
- 基因分析在77例患者中鉴定出66种COL4A3/A4/A5基因致病性变异。
- 免疫学表现异质,Gd-IgA1沉积或循环水平不一致。
关键数值与推荐
- 接受免疫抑制治疗评估的患者中,完全缓解率为7.1%(1/14),部分缓解率为64.3%(9/14)。
- 27例有随访数据患者末次访视中位年龄16.0(10.0-24.0)岁,11例(40.7%)达到肾脏终点。
临床怎么用
- 对IgAN-AS患者应关注蛋白尿水平,儿童患者肾病范围蛋白尿更常见。
- 基因检测有助于明确Alport综合征相关COL4A3/A4/A5变异。
- 免疫抑制治疗下部分缓解率较高,但完全缓解率低,需个体化评估。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In recent years, IgA nephropathy (IgAN) coexisting with Alport syndrome (AS) has been increasingly reported. However, the clinicopathological and molecular features, treatment, and prognosis of this entity have not been fully elucidated. METHODS: We first retrospectively analyzed pediatric patients with IgAN coexisting with AS (IgAN-AS) admitted to our center, and performed galactose-deficient IgA1 (Gd-IgA1) immunostaining on renal biopsy specimens. We then systematically searched PubMed, Scopus, Web of Science, Wanfang Data, and the China National Knowledge Infrastructure for publications reporting on patients with IgAN-AS. RESULTS: A total of 81 patients from 72 families were included. Microscopic hematuria was a universal finding. Nephrotic-range proteinuria was significantly more frequent in children than in adults (73.7% vs. 8.8%). Pathological findings confirmed the dual diagnosis, with mesangial IgA-dominant deposits and significant glomerular basement membrane abnormalities, including thinning (69.5%, 41/59) and typical AS-related changes (28.8%, 17/59). Genetic analysis identified 66 distinct pathogenic variants across COL4A3/A4/A5 genes in 77 patients. Immunologic findings were heterogeneous, with inconsistent Gd-IgA1 deposition or circulating levels. Among patients evaluated for treatment response, complete remission (CR) and partial remission (PR) were observed in 7.1% (1/14) and 64.3% (9/14), respectively, during immunosuppressive treatment. In 27 patients with follow-up data, the median age at last visit was 16.0 (10.0-24.0) years, and 11 (40.7%) reached the kidney end point. CONCLUSION: IgAN-AS appears to be a heterogeneous condition with potentially unfavorable kidney outcomes. Some patients exhibited both immune and structural injury, suggesting that biomarkers with high sensitivity and specificity for IgAN may aid in disease stratification.
引用
- Ying D, Zhang Y, Ma Y, et al. Systematic Review of IgA Nephropathy Coexisting With Alport Syndrome. Kidney Int Rep. 2026. PMID: 42027550. doi:10.1016/j.ekir.2026.106500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。